BUX — BioMark Diagnostics Balance Sheet
0.000.00%
- CA$26.27m
- CA$26.73m
- CA$0.16m
Annual balance sheet for BioMark Diagnostics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.612 | 0.878 | 0.383 | 0.072 | 0.157 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.016 | 0.027 | 0.082 | 0.034 | 0.043 |
Prepaid Expenses | |||||
Total Current Assets | 0.628 | 0.923 | 0.499 | 0.126 | 0.2 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.009 | 0.027 | 0.969 | 0.589 | 0.852 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 0.637 | 0.953 | 1.47 | 0.732 | 1.09 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.08 | 0.922 | 1.5 | 1.66 | 1.24 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 1.08 | 1.03 | 2.11 | 1.88 | 1.7 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -0.439 | -0.079 | -0.636 | -1.15 | -0.61 |
Total Liabilities & Shareholders' Equity | 0.637 | 0.953 | 1.47 | 0.732 | 1.09 |
Total Common Shares Outstanding |